Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Portola Pharmaceuticals (PTLA) PT Raised to $50 at Citi
March 4, 2019 6:58 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $50.00 (from $49.00) while maintaining a Buy rating as the company launches Andexxa. Nochomovitz is being executed well under the new CEOs leadership and should be owned as path to Andexxa growth is... More
Portola Pharma (PTLA) Misses Q4 EPS by 23c
March 1, 2019 8:08 AM ESTPortola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.34), $0.23 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $10.94 million.
For earnings history and earnings-related data on Portola Pharma (PTLA) click here.
... More